GPD2
Glycerol-3-phosphate dehydrogenase, mitochondrial
As of the edition of 20 October 2026, GPD2 (glycerol-3-phosphate dehydrogenase, mitochondrial, UniProt P43304) has 2 drugs tested at it and 20 companies on the list, 1 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P43304
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Inside the cell
- Disease areas
- Nutrition and metabolism; Hormones; Cancer; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue; Digestive system; Heart and blood vessels
- Registered trials of its drugs
- 1,613
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Metformin | Marketed | Phase 4 | none listed |
| EFB0027 | Went quiet | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 4 |
| Engaged | 15 |
| Total on the list | 20 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route B |
| Sanofi | Route B |
| Cheplapharm Arzneimittel | Route B |
The other 17 companies at GPD2
In the product20 companies in all; 17 are not named here, and no score is.
See the 20 companies at GPD2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.